Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...

Panelists discuss how CT-155, a 16-week interactive digital application, met its primary end point in clinical trials by ...

Boehringer Ingelheim plans to submit its app to treat under-addressed symptoms of schizophrenia for FDA clearance.

A new study by a research team at Université de Montréal highlights a critical lack of knowledge about the cognitive profiles ...

A major scientific review reveals a deep knowledge gap in how cognition is affected when schizophrenia and personality disorders occur together.

As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...

Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

A new study by a research team at Université de Montréal highlights a critical lack of knowledge about the cognitive profiles ...

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

A massive genomic study of over 1 million cases found that shared risk across 14 psychiatric disorders is reduced to 5 ...

Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences has initiated a Phase 3 study titled ‘A ...